Stock Events

Stock Events

Graf Acquisition Corp IV 

$8.3
14
+$0.4+5.06% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
178.05M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.2
-0.06
0.08
0.22
Expected EPS
N/A
Actual EPS
0.04

Financials

-Profit Margin
Profitable
2021
2022
0Revenue
4.55MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GFOR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Novartis offers CAR-T cell therapies, competing in the broader cell therapy market against NKGen's NK cell therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for cancer, similar to NKGen Biotech.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is focused on allogeneic CAR-T therapies, which are in the same therapeutic category as NKGen's work with NK cells.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing to develop cancer therapies, indirectly competing with NKGen by targeting similar indications with a different technology.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is developing programmed cellular immunotherapies, including NK and T-cell therapies, making them a direct competitor.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics' work on genomic medicines, including gene-edited cell therapies, places them in competition with companies developing cell-based cancer therapies.

About

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Show more...
CEO
Dr. Paul Y. Song M.D.
Employees
63
Country
US
ISIN
US3842721009

Listings

OTC Link
US
NKGNW
OTC Link
US
NKGN

0 Comments

Share your thoughts

FAQ

What is Graf Acquisition Corp IV stock price today?▼
The current price of GFOR is $8.3 USD — it has increased by +5.06% in the past 24 hours. Watch Graf Acquisition Corp IV stock price performance more closely on the chart.
What is Graf Acquisition Corp IV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Graf Acquisition Corp IV stocks are traded under the ticker GFOR.
What is Graf Acquisition Corp IV market cap?▼
Today Graf Acquisition Corp IV has the market capitalization of 178.05M
What were Graf Acquisition Corp IV earnings last quarter?▼
GFOR earnings for the last quarter are 0.04 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Graf Acquisition Corp IV revenue for the last year?▼
Graf Acquisition Corp IV revenue for the last year amounts to 0 USD.
What is Graf Acquisition Corp IV net income for the last year?▼
GFOR net income for the last year is 4.55M USD.
How many employees does Graf Acquisition Corp IV have?▼
As of April 01, 2026, the company has 63 employees.
In which sector is Graf Acquisition Corp IV located?▼
Graf Acquisition Corp IV operates in the Health Care sector.
When did Graf Acquisition Corp IV complete a stock split?▼
Graf Acquisition Corp IV has not had any recent stock splits.
Where is Graf Acquisition Corp IV headquartered?▼
Graf Acquisition Corp IV is headquartered in Santa Ana, US.